Presentation and outcome of pancreaticoduodenal tumors in Multiple Endocrine Neoplasia type 1 (MEN 1) syndrome Abstract #102

Introduction: Multiple endocrine neoplasia type 1 (MEN 1) is a rare autosomal dominant condition characterized by the development of parathyroid, pancreaticoduodenal endocrine and pituitaty tumors. Pancreaticduodenal endocrine tumors (PDETs) are a frequent manifestation of MEN 1, with a prevalence ranging from 30 to 75%, and represent a major cause of death in one-third of patients. There is continuing debate on their management, mainly on the optimal surgical strategy, due to their multicentricity and high recurrence rate.
Aim(s): To assess presentation and outcome of pancreaticoduodenal endocrine tumors (PDETs) in a monoinstitutional series of MEN1 patients.
Materials and methods: Prospective collected data of a cohort of MEN 1 patients observed at the internal medicine and surgical units of the University of Verona (Italy) were retrospectively analyzed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Maria Vittoria Davi'

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2879 Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
Introduction: Lung neuroendocrine tumors account for 25% of all neuroendocrine tumors. It is a heterogeneous group that meets morphological criteria; immunohistochemical and molecular; defining 4 groups: Typical and atypical carcinoid tumors, neuroendocrine carcinomas with large cell and small cells. Carcinoid syndrome is rare in these tumors and the treatment is based on surgery for localized forms and multimodal treatment for metastatic forms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hakima Kehili
#2764 Cystic Pancreatic Neuroendocrine Tumors. Can We Diagnose Them Preoperatively?
Introduction: Pancreatic neueroendocrine tumors rarely undergo cystic changes but they are often misdiagnosed as pancreatic mucinous cystadenoma, mucinous cystadenocarcinoma, serous cystadenoma, and solid and cystic papillary tumors, or pseudocyst.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova
#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery
Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Chiara Nessi
Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, ...
#2975 Next Generation Sequencing of Pancreatic Neuroendocrine Tumors in Russian Cohort
Introduction: The appearance of next generation sequencing (NGS), - a powerful high-performance method, allowed accumulation of a large amount of information concerning genetic and epigenetic patterns, however, the problem of matching clinical, histological picture with genetic structure in pNETs remains open.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: PhD Vladimir Trifanov